Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by ScootsMcgootson Feb 07, 2024 2:57pm
199 Views
Post# 35868143

Oncy is a Cult Pt. 2

Oncy is a Cult Pt. 2

I'd like to follow on from my last post which was deleted for abuse? I merely pointed out the failings of Oncolytics. 

Noteable appears to be paid in some fashion would be my best guess. At a minimum he does not know anything about science or medicine NOT ONCY related. I certainly wouldn't trust his 'studied opinion' in any context whatsoever if you are an average retail investor. 

Proof of concept he says CLTA is not a promising pathway. BMS has no less than 40 clinical trials for CLTA therapy Ipimilab currently underway. Furthremore Yergovy is a multibillion dollar drug. He would have you believe that an Oncolytic Virus company with ZERO clinical trials presently is a more promising path. And that he knows better than the scientific advisors for Bristol Meyers Squibb. Okay... I could go on but you get the point. Do not listen to this guy AT ALL UNLESS AT YOUR OWN PERIL. 

You know SEC rules would have required a filing for Andrew G's departure within 5 days as a director level position in the company, they never did it. Pancan announcement but never happened within the requisite period from when they would have known as well. All these characters on here every day. I am getting fraud vibes from ONCY. At a minimum management is willing to tilt the scales only in their favor. Should there be lawsuits? Probably, but it will never happen as you don't throw good money after bad. Be careful out there folks! 

 

<< Previous
Bullboard Posts
Next >>